Back to News
Nov 21, 2025 4:00 PM

Elanco Animal Health Stock Is Undervalued: Analyst

As the pet care industry experiences rapid growth, pharmaceutical companies are increasingly focusing on developing innovative treatments for companion animals.

ELAN is charging ahead with explosive momentum. Get the inside scoop here

KeyBanc Capital Markets initiated coverage on Elanco Animal Health Incorporated (NYSE:ELAN).

The company’s recent Innovation Products launches (Zenrelia and Credelio Quattro) are showing strong revenue growth, the analyst said in a note.

Analyst Steve Decher expects these and other Innovation Products to continue to drive revenue growth over the next few years (6-8% annual growth from 2025-2028 vs. low single digit from 2022-2024).

Also Read: Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

The analyst also expects margin expansion from a higher ...